Olon combines high-potency chemistry, linker-payload development and bioconjugation within one organisation, simplifying ADC development
2026 Development Plan Highlights Global Investments and Capacity Growth New York, NY – At
The Strategic collaboration makes biocatalysis commercially viable MILAN, Italy and BARCELONA, Spain – Olon,
Olon is ready to host productions in the new facility dedicated to ultra potent compounds
Olon’s Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API…
Olon’s Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections.
Olon, leading international API supplier, is delighted to announce an additional investment which will further expand its global platform for developing and producing potent and high potent active ingredients
CREATE A SCHOLARSHIP TO DEVELOP NEW PHOTOCHEMISTRY PROCESSES APPLIED TO THE INDUSTRIAL PRODUCTION OF
ACTIVE PHARMACEUTICAL INGREDIENTS
THE GROUP, LEADING API SUPPLIER AND EXPERT IN HIGHLY POTENT APIs, PRESENTS INVESTMENTS FOR 27 MILLION AND INAUGURATES A NEW LARGE SCALE HIGH CONTAINMENT PRODUCTION LINE
